Biologics, which appear to have a safer risk-to-benefit ratio compared to cyclosporine, have more or less supplanted this drug for psoriasis in most patients. Humira (adalimumab) is a commonly ...

Q. Is there any cure for psoriasis? A. There’s no cure for psoriasis yet, but there are many ways to get relief from the symptoms of this troublesome disease. Psoriasis is one of the most ...

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...

such as adalimumab, alefacept, efalizumab, etanercept, and infliximab). In a recent Japanese Society for Psoriasis Research analysis of 28,628 cases, herbal medicines (14.5%) ranked highest among ...

Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic ...

Adalimumab was the third TNF inhibitor to be approved for psoriasis, but has been gaining momentum in the market against etanercept, owing to superior efficacy data from clinical trials (Psoriasis ...

UnitedHealth to Remove AbbVie's Humira From Some US Drug Reimbursement ... differences in the risk for PsA among patients with psoriasis treated with interleukin (IL)-23 inhibitors and those ...

With approvals in rheumatoid arthritis, psoriasis, and Crohn's disease, Humira holds a wide range of indications, but biosimilar versions of the drug led to price erosion beginning in 2023 and ...